Jade Biosciences, INC. (JBIO) SEC Filings — 2025
16 SEC filings for Jade Biosciences, INC. (JBIO) in 2025.
Filings
- Jade Biosciences Files S-1 for $45M PIPE Resale; Nasdaq Listing Continues — S-1 · Dec 22, 2025
- Jade Biosciences, INC. 8-K Filing — 8-K · Dec 15, 2025
- JBIO's R&D Surge Drives $95M Loss Amid Autoimmune Pipeline Push — 10-Q · Nov 14, 2025
- Jade Biosciences Files 8-K with Material Agreements and Disclosures — 8-K · Oct 7, 2025
- Jade Biosciences Reports Director and Officer Changes — 8-K · Sep 9, 2025
- Jade Biosciences Boosts Cash to $220M Post-Merger, Losses Mount — 10-Q · Aug 13, 2025
- Jade Biosciences Announces Board Changes and Material Agreement — 8-K · Jul 1, 2025
- Jade Biosciences Files 8-K on Asset Disposition — 8-K · May 14, 2025
- Jade Biosciences Files 8-K with Major Corporate Updates — 8-K · May 1, 2025
- Aerovate Therapeutics Files 8-K — 8-K · Apr 29, 2025
- Aerovate Therapeutics Reports Q1 2025 Financials — 10-Q · Apr 25, 2025
- Aerovate Therapeutics Files 8-K Report — 8-K · Apr 23, 2025
- Aerovate Therapeutics Files 8-K — 8-K · Apr 21, 2025
- Aerovate Therapeutics Files 8-K — 8-K · Apr 9, 2025
- Aerovate Therapeutics Files 8-K — 8-K · Apr 7, 2025
- Aerovate Therapeutics Files 2024 10-K — 10-K · Mar 27, 2025